Management of Bcr-Abl-positive leukemias with dasatinib (Q37004660)

17 August 2017

1 reference

title

Management of Bcr-Abl-positive leukemias with dasatinib (English)

1 reference

17 August 2017

1 reference

ChEBI release 2020-05-28

Andreas Hochhaus

1

0 references

publication date

1 November 2007

1 reference

Expert Review of Anticancer Therapy

17 August 2017

1 reference

17 August 2017

7

1 reference

17 August 2017

11

1 reference

17 August 2017

1529-1536

1 reference

Philadelphia chromosome-positive leukemias: from basic mechanisms to molecular therapeutics

17 August 2017

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.11.1529

Chronic myeloid leukemia: why does it evolve from chronic phase to blast transformation?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.11.1529

Cytogenetic and molecular genetic aspects of chronic myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.11.1529

Clinical and epidemiologic burden of chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.11.1529

Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.11.1529

Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.11.1529

In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.11.1529

Resistance to targeted therapy in chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.11.1529

Loss of response to imatinib: mechanisms and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.11.1529

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.11.1529

The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.11.1529

Overriding imatinib resistance with a novel ABL kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.11.1529

Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.11.1529

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.11.1529

Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.11.1529

Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.11.1529

Sequence-specific modification of a beta-thalassemia locus by small DNA fragments in human erythroid progenitor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.11.1529

Molecular mechanism of hepcidin deficiency in a patient with juvenile hemochromatosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.11.1529

Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.11.1529

The early molecular response to imatinib predicts cytogenetic and clinical outcome in chronic myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.11.1529

Molecular monitoring of BCR-ABL as a guide to clinical management in chronic myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.11.1529

The significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phase

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.11.1529

Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.11.1529

Insights from pre-clinical studies for new combination treatment regimens with the Bcr-Abl kinase inhibitor imatinib mesylate (Gleevec/Glivec) in chronic myelogenous leukemia: a translational perspective.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.11.1529

Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.11.1529

Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.11.1529

Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.11.1529

Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.11.1529

10.1586/14737140.7.11.1529

21 January 2018

Identifiers

DOI

1 reference

release_7khoqlywwvgzdhnxtotdrqbfby

17 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/7khoqlywwvgzdhnxtotdrqbfby

mapped directly with Wikidata item

24 November 2022

based on heuristic

PubMed ID

18020922

1 reference

PubMed ID

18020922